Cannabis Investments

Cannabis Science Issues First Market and Revenue Guidance in Regards to the Top 10 Cancer Formulations the Company Intends Focus on over Next Ten Years

December 14, 2011

DENVER–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB: CBIS.ob), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that we have a variety of cannabis-based formulations that target critical ailments worldwide. Illnesses ranging from cancer to pain management give the company a large market and revenue base potential. As outlined on the company website www.cannabisscience.com our initial target of self-administered cancer formulations proves to be the fastest to market application as prompted by recent successful cannabis-based treatments outlined in earlier press releases issued by the Company.

Marketresearch.com says cancer is the second-leading cause of death in the United States, and the world market for cancer therapy is growing at a brisk double-digit pace of over 10% per year, with total treatments revenues surpassing $40 billion this year in the USA alone.

Current market research and analysis shows Cannabis Science in a position to capitalize on the current annual cancer revenues at the low end of scale at approximately 1% market share giving the company a projected $400 million total revenues per year less associated costs.

The Top Ten Cancers and their respective markets Cannabis Science intends to focus on in regards to their formulations are Basal Cell Carcinoma and Squamous Cell Carcinoma (Skin Cancers), Ductal Carcinoma (Breast Cancer), Colon Cancer, Glioma (Brain Tumor), Lung Cancer, Multiple Myeloma (Bone Marrow), Ovarian Cancer, Pheochromocytoma (Adrenal Gland), and Prostate Cancer.

Cannabis Science estimates that there are over 7 million patients who suffer from these cancers in the USA alone and who could potentially benefit from the Cannabis Science Based Extract formulations as they initially become available in states with appropriate medical marijuana laws.

Robert Kane, Investor Relations Manager stated, “Our primary goals here at Cannabis Science in regards to increasing shareholder value started with more efficient communication and increased guidance in regards to the revenue and earnings potential of their business model. With the establishment of the Facebook and Twitter accounts, and the incredible support they have given me, it has allowed Cannabis Science to answer and respond to shareholder inquiries much more efficiently than in the past. Now, with this release of this market and revenue guidance, I applaud Dr. Melamede and his team for accomplishing these goals, and doing it so in such an efficient manner. Cannabis Science vigilantly continues to work on their projections and forecasts of their products for potential conditions that Cannabis Science will focus on in the future these projections and forecasts include different global geographical market and different medical conditions going forward over the next ten years. I look forward to sharing that guidance as it approved.”

Dr. Robert Melamede, President of Cannabis Science stated, “This information contained in this guidance demonstrates that we have a viable business model. We will generate revenues from our strategic alliance with MEDBOX, as well as from our Cannabis Extract Based Formulations. These revenue streams, as well as additional ones that we are currently working on, will allow us to fund our FDA efforts on a national level while we test and develop products on the medical marijuana state level.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek, “intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Robert Kane, 561-234-6929
Investor Relations
rkane@kaneabis.com
or
Dr. Robert Melamede, President
www.cannabisscience.com
info@cannabisscience.com

View full post on News Releases

Cannabis Science Issues First Market and Revenue Guidance in Regards to the Top 10 Cancer Formulations the Company Intends Focus on over Next Ten Years

December 14, 2011

DENVER–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB: CBIS.ob), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that we have a variety of cannabis-based formulations that target critical ailments worldwide. Illnesses ranging from cancer to pain management give the company a large market and revenue base potential. As outlined on the company website www.cannabisscience.com our initial target of self-administered cancer formulations proves to be the fastest to market application as prompted by recent successful cannabis-based treatments outlined in earlier press releases issued by the Company.

Marketresearch.com says cancer is the second-leading cause of death in the United States, and the world market for cancer therapy is growing at a brisk double-digit pace of over 10% per year, with total treatments revenues surpassing $40 billion this year in the USA alone.

Current market research and analysis shows Cannabis Science in a position to capitalize on the current annual cancer revenues at the low end of scale at approximately 1% market share giving the company a projected $400 million total revenues per year less associated costs.

The Top Ten Cancers and their respective markets Cannabis Science intends to focus on in regards to their formulations are Basal Cell Carcinoma and Squamous Cell Carcinoma (Skin Cancers), Ductal Carcinoma (Breast Cancer), Colon Cancer, Glioma (Brain Tumor), Lung Cancer, Multiple Myeloma (Bone Marrow), Ovarian Cancer, Pheochromocytoma (Adrenal Gland), and Prostate Cancer.

Cannabis Science estimates that there are over 7 million patients who suffer from these cancers in the USA alone and who could potentially benefit from the Cannabis Science Based Extract formulations as they initially become available in states with appropriate medical marijuana laws.

Robert Kane, Investor Relations Manager stated, “Our primary goals here at Cannabis Science in regards to increasing shareholder value started with more efficient communication and increased guidance in regards to the revenue and earnings potential of their business model. With the establishment of the Facebook and Twitter accounts, and the incredible support they have given me, it has allowed Cannabis Science to answer and respond to shareholder inquiries much more efficiently than in the past. Now, with this release of this market and revenue guidance, I applaud Dr. Melamede and his team for accomplishing these goals, and doing it so in such an efficient manner. Cannabis Science vigilantly continues to work on their projections and forecasts of their products for potential conditions that Cannabis Science will focus on in the future these projections and forecasts include different global geographical market and different medical conditions going forward over the next ten years. I look forward to sharing that guidance as it approved.”

Dr. Robert Melamede, President of Cannabis Science stated, “This information contained in this guidance demonstrates that we have a viable business model. We will generate revenues from our strategic alliance with MEDBOX, as well as from our Cannabis Extract Based Formulations. These revenue streams, as well as additional ones that we are currently working on, will allow us to fund our FDA efforts on a national level while we test and develop products on the medical marijuana state level.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek, “intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Robert Kane, 561-234-6929
Investor Relations
rkane@kaneabis.com
or
Dr. Robert Melamede, President
www.cannabisscience.com
info@cannabisscience.com

View full post on News Releases

Cannabis Science Packaging its First Cannabis-Extract-Based Formulation Slated For October 2011 Colorado State Distribution As The First Analytical Reports And Production Runs Are Completed

October 13, 2011

DENVER,(BUSINESS WIRE) — Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that the initial product analyzing and production run has been completed and the commercial packaging process is now underway. This will be the first set of Cannabis Science brand formulations being released, scheduled for later this month through its producing lab and initial Colorado State licensed dispensary. The Company’s CEO, Dr. Robert Melamede, has chosen specially selected medical marijuana dispensaries in Colorado that will offer the Cannabis Science formulations to patients in accordance with Colorado State laws and regulations.

Dr. Robert Melamede, Ph.D., the Company’s CEO, said, “We hear from so many people wanting a reliable, high-quality formulation that they can self-administer to treat a wide variety ailments. A quality, standardized formulation is essential for long term care. As far as I know, we have the only formulation made from organically grown cannabis bud, and produced in a professional, Colorado State licensed, laboratory facility. Initially, we have chosen two facilities in Colorado to work with, both of the facilities were chosen for the quality of their botanicals and patient care. We are looking forward to expanding availability to other legal medical marijuana facilities and States along with an increased multiple formulation offerings.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

CONTACT:

Cannabis Science Inc.

Robert Kane

Investor Relations Management

info@cannabisscience.com

www.cannabisscience.com

1-561-234-6929

or

Dr. Robert J. Melamede Ph.D.

President & CEO

info@cannabisscience.com

www.cannabisscience.com

1-888-889-0888

View full post on News Releases

Cannabis Science Releases First Cannabis-Extract-Based Formulation Available Now at Cannabis Therapeutics, 957 E. Fillmore St, Colorado Springs, Colorado

October 27, 2011

DENVER–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce the successful release of the first Cannabis Science brand formulation. The Company has been receiving a constant flow of inquires via its website, emails, and telephone calls for cannabis-extract based medicines. For example, cancer patients seeking extract-based formulations for topical or internal use have frequently contacted Cannabis Science. Manufacturing and packaging has been completed and is now available through Cannabis Therapeutics for patient usage.

Cannabis Therapeutics
www.cannabistherapeutics.net
907 E Fillmore St.
Colorado Springs, CO 80907
(719) 633-7124

In light of the accumulating anecdotal reports of the successful cancer treatments with cannabis extracts, the Company will continue to keep patients updated on current peer-reviewed scientific literature supporting the historical and modern use of cannabis to treat “tumors”. Unlike conventional treatment, cannabis medicines have an outstanding safety profile allowing patients in states with medical marijuana laws to safely make informed decisions to legally self-administration of various cannabis-based preparations.

The first Cannabis Science Brand extract-based formulation is comprised of high quality oil packaged in oral dispensing syringes for patient self-administration for treatment. This is a critical milestone for the Company in bringing its first formulation to market. Other formulations will be made available soon to medical marijuana patients in Colorado through the Company’s vetted dispensaries. The Company’s intent is to work with specially appointed legal providers and laboratories to expand the availability of its formulations across the United States where legally available.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The first formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contacts
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Company Planting 300 Acres of Fiber-Variety Flax in Kingstree, South Carolina; Commencing Growing Trials as Part of the Initiative
PORTLAND, OR (September 20, 2010) —Naturally Advanced Technologies Inc., (OTCBB: NADVF, TSXV: NAT), the developers of the patented CRAiLAR process, announced today that they have created a sustainable, commercially viable complement to cotton using flax as a raw material.

After succ View full post on Naturally Advanced Technologies, Inc. News Feed